+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus

  • ID: 4655560
  • Report
  • February 2018
  • Region: Global
  • 39 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • ImmuPharma
  • Lilly
  • MORE
KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus

Summary

This KOL Insight briefing focuses on opinions of mid- to late-stage pipeline therapies in lupus.

The briefing includes analysis of KOL opinion on the following topic areas:
  • Development of Lupuzor for SLE
  • Lupuzor’s Phase III trial design
  • Lupuzor’s Phase IIb efficacy data in SLE
  • Anticipated future use of Lupuzor in SLE
  • Development of baricitinib in SLE
  • Endpoints used in baricitinib’s Phase II trial
  • Expectations for baricitinib’s Phase II trial results
  • Views on the increased risk of thromboembolic events seen with baricitinib in RA
  • Views on the risk of thromboembolic events in the lupus patient population
  • Concerns regarding herpes zoster in lupus patients
  • Impact of high infection rate with JAK inhibitor use in RA, on anticipated baricitinib use in SLE
  • Development of IFN? kinoid in SLE
  • IFNa kinoid vs. anifrolumab in SLE
Key Highlights:
  • Most KOLs flagged the need for more data to understand Lupuzor’s mechanism of action and elucidate its efficacy in lupus patients
  • KOLs were divided over Lupuzor’s efficacy in lupus based on its Phase IIb data, with some highlighting that it may be comparable to belimumab
  • Most KOLs had a positive opinion regarding baricitinib’s development in lupus, based on its data in other indications.
Scope
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our lupus key opinion leaders (KOLs)
  • In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based
  • Interviews performed in December 2017
  • KOL data is analyzed to produce: Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts.
Reasons to buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "Mid-to-Late Stage Pipeline Therapies in Lupus"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • ImmuPharma
  • Lilly
  • MORE
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ImmuPharma
  • AstraZeneca
  • Lilly
Note: Product cover images may vary from those shown
Adroll
adroll